CN EN
Contact Us

Contact Us

Product Portfolio

Pulse Medical offers comprehensive imaging and computational physiology solutions for coronary and peripheral intervention workflows.

Comprehensive Coronary Intervention Solutions

Integrating CCTA, coronary angiography, IVUS, and computational physiology with multimodal data to cover full-process coronary intervention management — from screening and planning to navigation and post-procedural optimization.

Comprehensive Peripheral Intervention Solutions

Integrated solutions for preprocedural assessment, intraprocedural guidance, and postprocedural follow-up in peripheral interventions.

Featured Publication

Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial

The Lancet, 2021; 398, 2149-2159
Coronary PCI procedures guided by Pulse Medical's QFR technology can significantly reduce the one-year risk of post-procedural adverse events by 35%, alleviate patient burden while keeping medical expenditures under reasonable control, and hold substantial socio-health-economic value.

*μFR in China branded as QFR or μQFR

Featured Publication

Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial

The Lancet, 2025; 405, 1491-1504
A PCI strategy guided by angiography-based computed FFR — AngioFFR (encompassing QFR and the next-generation μQFR technology derived from single-view angiography), including revascularization decision-making and procedural optimization — is non-inferior to IVUS-guided PCI in 12-month clinical outcomes and carries the added advantage of reducing stent implantation.

*μFR in China branded as QFR or μQFR

Featured Publication

Angiography-derived fractional flow reserve versus coronaryangiography to guide coronary artery bypass grafting in patientsundergoing surgical valve procedures with concomitant coronaryartery disease in China (FAVOR IV-QVAS): a multicentre, triple-blind, randomised trial

The Lancet, 2026; 407, 1161-1170
Compared with the conventional coronary angiography-guided strategy, coronary artery bypass grafting (CABG, bypass surgery) guided by Pulse Medical's proprietary quantitative flow ratio (QFR, including the next-generation µQFR) technology significantly improves postoperative clinical outcomes in patients with concomitant valvular disease and coronary artery disease.

*μFR in China branded as QFR or μQFR

Featured Publication

Complete Revascularization Guided by Functional Coronary Angiography in STEMI

N Engl J Med, 2026; DOI: 10.1056/NEJMoa2605373
The AIR-STEMI trial (n=1823) demonstrates that QFR-guided complete revascularization in STEMI multivessel disease reduces major adverse events by 38% (8.9% vs 13.7%, P<0.001) and contrast-associated kidney injury with major bleeding, offering a safer strategy.

*μFR in China branded as QFR or μQFR

Featured Publication

2024 ESC Guidelines for the management of chronic coronary syndromes

European Heart Journal (2024) 00, 1-123
China-originated quantitative flow ratio (QFR) technology was formally incorporated and received a Class I (the highest-level) recommendation.

*μFR in China branded as QFR or μQFR

Featured Publication

Guidelines for percutaneous coronary intervention (2025)

Zhonghua Xin Xue Guan Bing Za Zhi. 2025 Jul 24;53(7):717-745.
Pulse Medical's proprietary quantitative flow ratio (QFR) technology, backed by its exceptional clinical value and robust evidence-based data, is explicitly recommended by current guidelines (Class I, Level A) for coronary physiological assessment and has become one of the key tools guiding PCI (percutaneous coronary intervention) decision-making.

*μFR in China branded as QFR or μQFR

Featured Publication

Applied coronary physiology for planning and guidance of percutaneous coronary interventions. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology

EuroIntervention, 2023;19:464-481; DOI: 10.4244/EIJ-D-23-00194
The EAPCI European expert consensus states that QFR is the only angiography-based physiological index prospectively validated and demonstrated to improve clinical outcomes, applicable for pre-PCI planning, virtual stenting simulation, and post-PCI functional assessment to guide precision intervention.

*μFR in China branded as QFR or μQFR

Featured Publication

Practical Application of Coronary Physiologic Assessment: Asia-Pacific Expert Consensus Document: Part 1

JACC: Asia, 2023;3(5):689-706; DOI: 10.1016/j.jacasi.2023.07.003
The Asia-Pacific expert consensus systematically describes the clinical application of image-based physiologic assessment including QFR. Based on evidence from FAVOR III China and other studies, it recommends QFR-guided PCI to reduce stent implantation and improve clinical outcomes, supporting virtual stenting planning and post-procedural efficacy verification.

*μFR in China branded as QFR or μQFR

Pulse Medical at POPAI 2026: Highlights from Our Special Symposium on Imaging-Based Physiological Assessment

2026-09-22

  • Publication Spotlight | AI-Empowered CCTA-Angiography Fusion for CTO PCI

    2026-09-10

  • AIR-STEMI: A Milestone Study — Functional Coronary Angiography Redefines Complete Revascularization in STEMI

    2026-08-30

  • VERMONT μQFR Study Validates Single-Projection 2D-μQFR as a Practical, Wire-Free Alternative to Invasive FFR

    2026-08-23

  • Next Horizon. Reshaping precision cardiology, hashtag#CtaPlus guided optimal PCI.

    2026-08-22

  • New Research | Understanding the Impact of Hydrostatic Pressure on FFR

    2026-08-14